Cardiovascular Risk in Gout Patients Cardiovascular Safety of Febuxostat or Allopurinol in Participants with Gout and Cardiovascular Comorbidities (CARES)

被引：1
|
作者：
Mueller-Wieland, D. [1 ]
Nitschmann, S. [1 ]
机构：
[1] Univ Klinikum RWTH Aachen, Med Klin 1, Pauwelsstr 30, D-52074 Aachen, Germany
来源：
INTERNIST | 2018年 / 59卷 / 11期
关键词：
URIC-ACID;
D O I：
10.1007/s00108-018-0486-2
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：1224 / 1228
页数：5
相关论文
共 50 条
  • [41] OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH GOUT TREATED WITH FEBUXOSTAT
    Quilis, N.
    Andres, M.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 1636 - 1636
  • [42] Gout lessons from 2018: CARES, a direct comparison of febuxostat vs allopurinol, and CANTOS, IL1 blocker for cardiovascular risk minimisation
    Tim L. Th. A. Jansen
    Matthijs Janssen
    Clinical Rheumatology, 2019, 38 : 263 - 265
  • [43] Gout lessons from 2018: CARES, a direct comparison of febuxostat vs allopurinol, and CANTOS, IL1 blocker for cardiovascular risk minimisation
    Jansen, Tim L. Th. A.
    Janssen, Matthijs
    CLINICAL RHEUMATOLOGY, 2019, 38 (01) : 263 - 265
  • [44] Limitations in Assessing Cardiovascular Risk of Febuxostat in Patients With Gout and Cardiovascular Morbidities: Comment on the Article by Choi et al
    Abeles, Aryeh M.
    Pillinger, Michael H.
    ARTHRITIS & RHEUMATOLOGY, 2019, 71 (06) : 1023 - 1024
  • [45] Risk of Cardiovascular Events in Older Patients with Gout Initiating Febuxostat Versus Allopurinol: A Population-Based Cohort Study
    Zhang, MaryAnn
    Liu, Jun
    Kang, Eun Ha
    Desai, Rishi J.
    Neogi, Tuhina
    Solomon, Daniel H.
    Kim, Seoyoung C.
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [46] Assessment of Cardiovascular Risk in Older Patients With Gout Initiating Febuxostat Versus Allopurinol: Population-Based Cohort Study
    Zhang, MaryAnn
    Solomon, Daniel H.
    Desai, Rishi J.
    Kang, Eun Ha
    Liu, Jun
    Neogi, Tuhina
    Kim, Seoyoung C.
    CIRCULATION, 2018, 138 (11) : 1116 - 1126
  • [47] CARDIOVASCULAR SAFETY OF FEBUXOSTAT IN PATIENTS WITH GOUT OR HYPERURICEMIA: A SYSTEMATIC REVIEW OF RANDOMIZED CONTROLLED TRIALS
    Ghossan, R.
    Aitisha, O.
    Fayad, F.
    Richette, P.
    Bardin, T.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 523 - 523
  • [48] Cardiovascular Safety of Febuxostat in Patients with Gout or Hyperuricemia: A Systematic Review of Randomized Controlled Trials
    Ghossan, Roba
    Tabesh, Ouidade Aitisha
    Fayad, Fouad
    Richette, Pascal
    Bardin, Thomas
    ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 2203 - 2205
  • [49] Cardiovascular Risks of Probenecid Versus Allopurinol in Older Patients With Gout
    Kim, Seoyoung C.
    Neogi, Tuhina
    Kang, Eun Ha
    Liu, Jun
    Desai, Rishi J.
    Zhang, MaryAnn
    Solomon, Daniel H.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 71 (09) : 994 - 1004
  • [50] Implications of the Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Morbidities Trial and the Associated Food and Drug Administration Public Safety Alert (vol 70, pg 1702, 2018)
    Neogi, Tuhina
    ARTHRITIS & RHEUMATOLOGY, 2018, 70 (12) : 2086 - 2086
12345